Global Inhalation CDMO Market Size Likely to Grow at a CAGR of 5.9% By 2033

Global Inhalation CDMO Market size was valued at USD 8.5 Billion in 2024 and is expected to reach USD 12.6 Billion by 2033, at a CAGR of 5.9% during the forecast period 2024 - 2033.

Inhalation CDMO Market Overview

Inhalation CDMO is a company that specializes in inhalation goods. These groups offer full-service solutions for the creation, production, and testing of inhalation-based drugs and treatments to biotech businesses, pharmaceutical corporations, and other customers.

The rising demand for inhalation Contract Development and Manufacturing Organisation (CDMO) services is a global trend, driven by the developing global market for inhalation medicines as well as the rising prevalence of respiratory disorders.

Effective inhalation medicines and delivery methods are more important than ever due to the increase in the incidence of respiratory infections, COPD, and asthma. Pharmaceutical businesses are using inhalation-focused CDMOs more frequently to take advantage of their experience with product research, formulation, and production.

Furthermore, the need for creative breathing solutions is fueled by the movement towards tailored medicine and focused drug delivery systems. Pharmaceutical businesses may also expedite time-to-market for innovative medications, save expenses, and streamline operations by outsourcing the research and production of inhalation products.

As a result, the confluence of industry dynamics, technology developments, and healthcare requirements is driving a substantial increase in the worldwide inhalation CDMO market.

By product, the API segment held the highest market share in 2023 and is expected to keep its dominance during the forecast period 2024-2033. The emergence of specialized pharmaceuticals and personalized treatment has led to a trend in the active pharmaceutical ingredient (API) industry: a growing need for sophisticated and specialist APIs. This development demands specialized knowledge and cutting-edge production methods.

By services, the formulation development segment held the highest market share in 2023 and is expected to keep its dominance during the forecast period 2024-2033. The growing emphasis on targeted drug delivery systems and personalised medicine in formulation development is a noteworthy trend.

The goal is to maximise efficacy and reduce adverse effects by customising formulations to the demands of each patient and the unique features of their condition.

The growing need for specialised services in the CDMO market for inhalation goods in North America is a notable trend, fueled by the region's strong pharmaceutical sector, strict regulatory requirements, and focus on efficiency and innovation.

A contract development and manufacturing organisation (CDMO), Recipharm AB (Recipharm) provides manufacturing, development, and technology services.

Report Scope

CMI has comprehensively analyzed the Global Inhalation CDMO market. The driving forces, restraints, challenges, opportunities, and key trends have been explained in depth to depict in depth scenario of the market. Segment wise market size and market share during the forecast period are duly addressed to portray the probable picture of this Global Inhalation CDMO industry.

The competitive landscape includes key innovators, after market service providers, market giants as well as niche players are studied and analyzed extensively concerning their strengths, weaknesses as well as value addition prospects. In addition, this report covers key players profiling, market shares, mergers and acquisitions, consequent market fragmentation, new trends and dynamics in partnerships.

List of the prominent players in the Inhalation CDMO Market:

• Recipharm AB
• AptarGroup Inc.
• Hovione
• Vectura Group Ltd
• Nemera
• Kindeva
• H&T Presspart
• Sanner GmbH
• Stevanato Group
• Medspray
• ICONOVO AB
• Lonza
• Gerresheimer AG
• Catalent
• Thermo Fisher Scientific Inc.
• Lubrizol Life Science
• Enteris BioPharma
• Cambrex Corporation
• INKE
• Piramal Pharma Limited
• Lupin
• Others

The Inhalation CDMO Market is segmented as follows:

By Service

• Formulation Development
• Device Development and Manufacturing
• Clinical Manufacturing
• Scale-up and Tech Transfer
• Quality Control and Quality Assurance
• Technology and Innovation
• Regulatory Assistance
• Analytical Services

By Product

• API
  • API Substrate
  • Large Molecule
  • Small Molecule
• Inhalation Platform
  • Dry Powder Inhaler (DPIs)
  • Metered Dose Inhaler (MDIs)
  • Soft Mist Inhaler

By Company Size

• Large
• Medium
• Small

By Scale of Operation

• Preclinical
• Clinical
• Commercial

Regional Coverage:

North America

• U.S.
• Canada
• Mexico
• Rest of North America

Europe

• Germany
• France
• U.K.
• Russia
• Italy
• Spain
• Netherlands
• Rest of Europe

Asia Pacific

• China
• Japan
• India
• New Zealand
• Australia
• South Korea
• Taiwan
• Rest of Asia Pacific

The Middle East & Africa

• Saudi Arabia
• UAE
• Egypt
• Kuwait
• South Africa
• Rest of the Middle East & Africa

Latin America

• Brazil
• Argentina
• Rest of Latin America